CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Clenbuterol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01942590
NCT01942590Phase 2Completed

A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy

Dwight Koeberl, M.D., Ph.D.·interventional·Posted Sep 16, 2013·Updated Jul 2, 2019

In Brief

A Phase 2 clinical trial evaluating Clenbuterol and Placebo for Pompe Disease. Completed, enrolled 17 participants across 1 site.

Detailed Summary

Funding Source- FDA OOPD The purpose of this study is to investigate the safety and efficacy of clenbuterol on motor function in individuals with late-onset Pompe disease (LOPD) who are treated with enzyme replacement therapy (ERT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPompe Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 16, 2013
Enrollment StartSep 1, 2013
Primary CompletionSep 2, 2016
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 12.8 years ago

Interventions

Clenbuteroldrug

Placebodrug